Correction of Autonomic and Cognitive Disturbances in Patients With Non-Alcoholic Fatty Liver Disease

Abstract

The aim: To explore the features of the congnitive (CD) and neurovegetative dysfunctions (NVD) of patients with different forms of non-alcoholic fatty liver disease NAFLD (nonalcoholic fatty hepatosis (NAFH) and non-alcoholic steatohepatitis (NASH)) and type 2 diabetes mellitus (T2DM), as well as their dynamics against the background of complex therapy using armadin (2-ethyl-6-methyl-3-hydroxypyridine succinate). Materials and methods: 50 patients with NAFLD (24 patients with NAFH and 26 patients with NASH) and T2DM were examined. Dysfunction of central and vegetative nervous system was carried out with the help of neuro-psychometric testing. Results: The analysis of the conducted research before treatments indicates the NVD in the surveyed patients. Cognitive dysfunctions (mostly mild and moderate) was revealed in all of our patients in both groups. The most pronounced disturbances before treatments were determined in the areas of attention and concentration, memory, less pronounced – visually constructive area, especially among patients with NASH and T2DM. Stressful situations have a pronounced impact on the lives of these patients, but they are not critical enough to any issues. Patients of Group 2 before treatments had the lowest level of resistance to stress. They found a slight vulnerability even from minor impacts. Conclusions: In patients with NAFLD and T2DM, congnitive and neurovegetative dysfunctions were found, according to neuro-psychometric testing. Complex therapy using 2-ethyl-6-methyl-3-hydroxypyridine succinate is an effective and safe method for the correction of congnitive and neurovegetative dysfunctions in patients with NAFLD and T2DM.

Application of non-invasive methods of assessment of steatosis and fibrosis in chronic diffuse liver diseases of various etiologies

“…The medico-social significance of the diagnosis of CDLD is due to a significant increase in the number of patients with the specified pathology, especially among people of working age, an increase in the percentage of mortality from complications, as well as an increase in the influence of various risk factors (hepatotoxic doses of alcohol, uncontrolled intake of drugs with an undesirable hepatotoxic effect, viral infections, nutritional features, environmental factors, etc.) [3,14,15].…”

“…According to epidemiological studies, the incidence of CDLD worldwide varies from 28.01 to 52.34 per 1,000 indi-viduals per year, with a prevalence of 10-40 % in the population [2]. Chronic liver diseases represent a major global health burden and account for approximately 2 million deaths an nually worldwide [3]. The main etiologies of chronic liver disease are considered to be viral hepatitis, alcohol-related damage, metabolic disorders, as well as autoimmune and genetic di seases, toxic and cholestatic liver injuries [4][5][6].…”